Plus   Neg

Ark Therapeutics Ink Manufacturing Pact With Laurantis Pharma - Quick Facts

Ark Therapeutics Group Plc (AKT.L) Monday announced that it has been selected to manufacture and supply Lymfactin to Laurantis Pharma under a conditional agreement.

The leading viral product focused contract development and manufacturing services company further stated that it has signed a manufacturing agreement with Laurantis Pharma, a privately held clinical-stage biotechnology company with a broad portfolio of first-in-class products based on two proprietary technologies, for Production of Lymfactin Investigational Treatment for Breast Cancer-Associated Lymphedema.

The Group stated that the agreement is subject to Laurantis receiving regulatory approval to commence its phase I clinical trial. Further, specific terms of the agreement between the two companies have not been disclosed.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Walt Disney World, the Orlando, Florida-based entertainment complex, is easing the health safety guidelines that were rolled out to prevent the spread of the ongoing COVID-19 pandemic. The complex is ending temperature checks in a phased manner following the advice of the Centers for Disease Control and Prevention (CDC) and local health officials. Frito-Lay North America, the convenient foods division of food and beverages giant PepsiCo, Inc., is recalling select Ruffles All Dressed Potato Chips citing the possible presence of undeclared milk ingredients, a known allergen, the U.S. Food and Drug Administration said. According to the agency, the recalled products may have distributed regionally to Walmart's Sam's Club Warehouses. Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced Friday that they have initiated the Biologics License Application (BLA) process with the U.S. Food and Drug Administration (FDA) for approval of their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. The companies initiated...
Follow RTT